An Open Label Study of Exploratory Pharmacogenomics and Pharmacologic Effects of Neoadjuvant Oral Temsirolimus in Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have a High Risk of Relapse

Inclusion Criteria

Inclusion criteria:

- Histologically confirmed diagnosis of adenocarcinoma of the prostate gland via a
minimum of 6 core biopsy samples.

- Subjects must be a candidate for radical prostatectomy

- No evidence of metastatic disease as determined by CT scans and bone scans

- More criteria apply

Exclusion Criteria:

- Subjects from whom sufficient diagnostic biopsy material is not available for full
characterization of the tumor

- Active Infection requiring antibiotic therapy, or serious intercurrent illness,
active bleeding, or ongoing urinary tract infection necessitating rapid or emergent
surgical resection

- Subjects who have had hormonal injection or implants which will last longer than 6
months

- More criteria apply